New Blood Test Shows Promise in Catching One of the Deadliest Cancers Early
Summary
A new blood test called PANXEON can detect early-stage pancreatic cancer by measuring three markers in the blood and using artificial intelligence to analyze them. This test showed it could find early cancer in 87% of cases and may help doctors treat the disease sooner.Key Facts
- Pancreatic cancer is hard to detect early because the pancreas is deep inside the body and symptoms often appear late.
- More than 67,000 people are diagnosed with pancreatic cancer each year in the U.S.
- Current tests rely on a single marker called CA19-9, which has limitations.
- PANXEON measures three signals in the blood: circulating microRNAs, exosomal microRNAs, and CA19-9.
- The test uses AI to combine these markers into one score predicting cancer risk.
- It correctly identified early-stage (1 and 2) pancreatic cancer in 87% of nearly 1,800 people tested across multiple countries.
- The test had a low false-positive rate: about 3% in low-risk people and 16% in high-risk groups.
- PANXEON also found advanced precancerous changes in about 64% of cases, which could help catch cancer before it develops.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
